These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 38456703)

  • 21. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
    Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
    EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection.
    Curlin ME; Bates TA; Guzman G; Schoen D; McBride SK; Carpenter SD; Tafesse FG
    Med; 2022 Dec; 3(12):827-837.e3. PubMed ID: 36198311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong.
    Zhou R; Liu N; Li X; Peng Q; Yiu CK; Huang H; Yang D; Du Z; Kwok HY; Au KK; Cai JP; Fan-Ngai Hung I; Kai-Wang To K; Xu X; Yuen KY; Chen Z
    Lancet Reg Health West Pac; 2023 Mar; 32():100660. PubMed ID: 36591327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals.
    Mak WA; Visser W; van der Vliet M; Markus HY; Koeleman JGM; Ong DSY
    J Med Virol; 2023 Aug; 95(8):e28989. PubMed ID: 37565645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralizing activity of a third dose of CoronaVac against Omicron subvariants within a 20-month follow-up study.
    Cao C; Guo Q; Dai Y; Jiang J; Liu M; Ji T; Zhou P; Gong F
    Hum Vaccin Immunother; 2023 Aug; 19(2):2242217. PubMed ID: 37529941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.
    Chan RWY; Liu S; Cheung JY; Tsun JGS; Chan KC; Chan KYY; Fung GPG; Li AM; Lam HS
    Front Immunol; 2021; 12():744887. PubMed ID: 34712232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal analysis of memory Tfh cells and antibody response following CoronaVac vaccination.
    Zhou P; Cao C; Ji T; Zheng T; Dai Y; Liu M; Jiang J; Sun D; Bai Z; Lu X; Gong F
    JCI Insight; 2023 Aug; 8(15):. PubMed ID: 37384407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19.
    Zhao W; Chen W; Li J; Chen M; Li Q; Lv M; Zhou S; Bai S; Wang Y; Zhang L; Zhang P; Wang J; Zheng Q; Wu J
    mBio; 2022 Jun; 13(3):e0018122. PubMed ID: 35475648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased antibody titers but induced T cell AICD and apoptosis response in COVID-19 convalescents by inactivated vaccine booster.
    Zhao J; Zhang H; Jiang L; Cheng F; Li W; Wang Z; Liu H; Li S; Jiang Y; Li M; Li Y; Liu S; Fang M; Zhou X; Ye X; Zhao S; Zheng Y; Meng S
    Microbiol Spectr; 2024 Mar; 12(3):e0243523. PubMed ID: 38319108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
    Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S
    Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection.
    Cheng SS; Mok CK; Li JK; Ng SS; Lam BH; Jeevan T; Kandeil A; Pekosz A; Chan KC; Tsang LC; Ko FW; Chen C; Yiu K; Luk LL; Chan KK; Webby RJ; Poon LL; Hui DS; Peiris M
    J Clin Virol; 2022 Nov; 156():105273. PubMed ID: 36081282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.
    Wang Q; Yang C; Yin L; Sun J; Wang W; Li H; Zhang Z; Chen S; Liu B; Liu Z; Shi L; Liu X; Guan S; Wang C; Qu L; Feng Y; Niu X; Feng L; Zhao J; Li P; Chen L; Zhong N
    Signal Transduct Target Ther; 2023 Apr; 8(1):167. PubMed ID: 37069171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
    Assawakosri S; Kanokudom S; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Yorsaeng R; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Honsawek S; Poovorawan Y
    J Infect Dis; 2022 Oct; 226(8):1372-1381. PubMed ID: 35267040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history.
    Hornsby H; Nicols AR; Longet S; Liu C; Tomic A; Angyal A; Kronsteiner B; Tyerman JK; Tipton T; Zhang P; Gallis M; Supasa P; Selvaraj M; Abraham P; Neale I; Ali M; Barratt NA; Nell JM; Gustafsson L; Strickland S; Grouneva I; Rostron T; Moore SC; Hering LM; Dobson SL; Bibi S; Mongkolsapaya J; Lambe T; Wootton D; Hall V; Hopkins S; Dong T; Barnes E; Screaton G; ; Richter A; Turtle L; Rowland-Jones SL; Carroll M; Duncan CJA; Klenerman P; Dunachie SJ; Payne RP; de Silva TI
    Nat Commun; 2023 Aug; 14(1):5065. PubMed ID: 37604803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
    Zhang Y; Qu JW; Zheng MN; Ding YX; Chen W; Ye SD; Li XY; Li YK; Liu Y; Zhu D; Jin CR; Wang L; Yang JY; Zhai Y; Wang EQ; Meng X
    Biomed Environ Sci; 2023 Jul; 36(7):614-624. PubMed ID: 37533385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.
    Verburgh ML; van Pul L; Grobben M; Boyd A; Wit FWNM; van Nuenen AC; van Dort KA; Tejjani K; van Rijswijk J; Bakker M; van der Hoek L; Schim van der Loeff MF; van der Valk M; van Gils MJ; Kootstra NA; Reiss P
    Microbiol Spectr; 2023 Jun; 11(3):e0115523. PubMed ID: 37166335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection.
    Goto T; Chong Y; Tani N; Susai N; Yoshinaga T; Sasaki T; Taniguchi M; Kusakabe T; Shimono N; Akashi K; Ikematsu H
    Vaccine; 2023 Nov; 41(47):7019-7025. PubMed ID: 37858449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.